Skip to main content

Right-to-Try Bill Passes the Senate

The legislation removes restrictions for seriously ill patients to access experimental treatments that have not received FDA approval.

Written byCatherine Offord
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

PIXABAY, VAL-GB Abill allowing seriously ill patients to obtain access to experimental, unapproved treatments passed the US Senate in a unanimous vote on Thursday (August 3). The legislation, known as the Right to Try Act, expands on similar laws already passed in 37 states, and eliminates the requirement for patients to obtain permission from the US Food and Drug Administration (FDA) to purchase treatments that are still undergoing evaluation.

“These are real people facing their mortality with no hope,” Senator Ron Johnson (R-WI), who sponsored the bill, said from the Senate floor. “This right-to-try piece of legislation will give those individuals and their family hope.”

The current bill is an updated version of legislation that Johnson proposed in January, and was passed as part of a deal after the Senator threatened to delay a critical FDA funding reauthorization bill unless a vote took place on the right-to-try legislation. Unlike the original version, the now-passed legislation requires that safety problems occurring in right-to-try situations are reported to the FDA. It also prevents drug companies from charging patients more than the production cost for the treatment itself.

Critics argue that the measure is unnecessary, as the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo